Study of tagraxofusp reports 90 percent response rate for deadly blood cancer with no prior available therapies

Naveen Pemmaraju, M.D.

HOUSTON ― An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive – and often fatal bone marrow and blood disorder – for which there are no existing approved therapies. Study findings were published in this week’s online issue of the New England […]

Patrick Carter, M.D., M.B.A., F.A.A.F.P. New Board Member of American Heart Association Houston Division Board

HOUSTON (March 18, 2019) – The American Heart Association’s mission is to be a relentless force for a world of longer, healthier lives – and it starts with solid leadership. Patrick Carter, M.D., M.B.A., F.A.A.F.P., Chief of Family Medicine and Medical Director of Care Coordination and Quality Improvement at Kelsey-Seybold Clinic, began a two-year term as a board member of the American Heart Association Houston Board in November 2018. Dr. Carter joins a robust team of […]

Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer according to MD Anderson study

Vassiliki Papadimitrakopoulou, M.D.

Test more accurately identifies four mutations for which FDA-approved drugs exist and offers faster turn-around time between initial testing and commencement of therapy A multi-center study led by researchers at The University of Texas MD Anderson Cancer Center revealed that a liquid biopsy test called Guardant360®, is comparable to standard tissue biopsies in detection of advanced non-small cell lung cancer (NSCLC), has a faster turn-around time, and has the potential to more specifically pinpoint biomarkers crucial for molecular therapy. […]

MD Anderson notes passing of Waun Ki Hong – innovator, mentor, colleague

Waun Ki Hong, M.D.

Former Cancer Medicine leader leaves a high-impact legacy for cancer patients, physicians HOUSTON – Waun Ki Hong, M.D., a trail-blazing physician-scientist and mentor whose clinical research innovations led to successful organ-sparing cancer treatment, advanced the field of targeted therapy and launched chemoprevention, died Wednesday at his home in California. Hong, 76, retired from The University of Texas MD Anderson Cancer Center as head of the Division of Cancer Medicine in 2014. He remained as a […]

Checkpoint inhibitor shrinks advanced squamous cell skin cancer

Michael Migden, M.D.

MD Anderson-led clinical trial shows nearly 50 percent of patients respond to cemiplimab HOUSTON – Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of a common skin cancer, an international team led by a researcher at The University of Texas MD Anderson Cancer Center reports in the New England Journal of Medicine. “These results mark a potential paradigm shift in the treatment of patients with […]

Researchers compose guidelines for handling CAR T cell side effects

HOUSTON — Immune-cell based therapies opening a new frontier for cancer treatment carry unique, potentially lethal side effects that provide a new challenge for oncologists, one addressed by a team led by clinicians at The University of Texas MD Anderson Cancer Center with proposed guidelines for systematically dealing with the toxicities of these drugs. Their work, published today in Nature Reviews Clinical Oncology, confronts the two main side effects of chimeric antigen receptor T-cells, known as CAR […]

Genetically enhanced, cord-blood derived immune cells strike B-cell cancers

HOUSTON – Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report in the journal Leukemia. The team’s preclinical research shows that natural killer cells derived from donated umbilical cords can be modified to seek and destroy some types of leukemia and […]

Memorial Hermann Mischer Neuroscience Associates Welcomes Neurologist Hamid S. Hamdi, M.D.

Dr. Hamid Hamdi

Memorial Hermann Mischer Neuroscience Associates (MNA) is pleased to announce the addition of board-certified neurologist Hamid S. Hamdi, M.D. Dr. Hamdi will join us as a general neurologist at Mischer Neuroscience Associates-Sugar Land and Mischer Neuroscience Associates-Katy. “We are pleased to have Dr. Hamdi as a part of our team of talented neurologists at Memorial Hermann Mischer Associates,” said Dong Kim, M.D., Director of the Memorial Hermann Mischer Neuroscience Institute at the Texas Medical Center […]

Vietnam War Veteran and Prominent Houston Doctor Authors Peaceful Bones Memoir after Returning Arm Bone to Vietnamese Soldier

Book Proceeds Benefit Texas Heroes and Hoa Binh Peace Village Houston author, retired urologist and Vietnam War veteran Samuel D. Axelrad, M.D. recently published his first memoir titled Peaceful Bones. The book is based on the true story of Dr. Axelrad’s experience as a Vietnam War army surgeon where he finds himself helping not only American soldiers but hundreds of Vietnamese citizens both wounded and ill. Peaceful Bones is about one special patient named Hung […]

Get the Facts – Stroke vs. Heart Attack Seminar

Dr. Larry Tran, neurologist

As with most things in life, a little awareness can go a long way. This is especially true when it comes to your health. “It may not get as much attention as other serious diseases, but stroke is the fifth leading cause of death and the primary cause of serious long-term disability for Americans,” said Larry Tran, M.D., a board-certified neurologist with the Neuroscience & Spine Center at Houston Methodist Sugar Land Hospital. A stroke […]